Mesothelioma
Primary Outcome Measures Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year. ] Inclusion Criteria Signed consent to long-term follow-up on protocol PA17-0483 Patients with advanced clear cell renal cell carcinoma, osteosarcoma or mesothelioma, with an…
There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery. The six-month survival was 87…
A specific type of radiation could be useful for the treatment of mesothelioma. Carbon-ion beam irradiation along with the chemotherapy drug cisplatin could potentially stop the growth of pleural mesothelioma tumors. Research was conducted at a carbon ion center in Chiba, Japan and results have been published to the American Journal of Cancer Research. Carbon…
Patients with thoracic and abdominal mesothelioma can extend survival when they are given aggressive surgery. This news came from a study at Baylor College of Medicine in Houston. When patients are given bicavity cytoreductive surgery, they had a median survival of 58.2 months. The results were published in December in the Journal of Thoracic and…
Immunotherapy before aggressive surgery shows great promise for pleural mesothelioma. The combination has shown that it can improve survival for a group of patients with pleural mesothelioma in a phase II study at Baylor College of Medicine. The treatment uses two immune checkpoint inhibitors, durvalumab and tremelimumab. The two drugs have shown that they can…
Primary Outcome Measures Progression free survival [ Time Frame: From randomisation up to 2 years of follow up ] Defined as the time from randomisation to the date of disease progression Overall survival [ Time Frame: From randomisation up to 2 years of follow up ] defined as the time from randomisation to the date of death from any cause. Secondary Outcome Measures…
Primary Outcome Measures Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD) [ Time Frame: 28 days during 1st cycle ] Determine the MTD and/or MAD of anti GP88 monoclonal antibody (AG-01) in subjects with advanced/refractory solid tumor malignancies for which no effective therapies exist. Antitumor Activity of AG-01 by Overall Response Rate (ORR) [ Time Frame: Every 56 Days ] To evaluate…
Mesothelioma diagnoses have almost doubled in the last 30 years, highlighting the need for better care and more ways to regulate and reduce asbestos exposure. There were around 35,000 people diagnosed with mesothelioma in 2019, while in 1990 there were around 19,000 people diagnosed. This information was released by the Clinical Research Center at Shandong…
A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of Opdivo and Yervoy. The combination…
Primary Outcome Measures Number of participants with adverse events (AEs) [ Time Frame: Through 30 days after the last study treatment; approximately 7 months ] Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Number of participants with laboratory abnormalities [ Time Frame: Through 30 days…
